74 results about "Elafin" patented technology

The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cosmetically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease).

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and/or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP_79-108, BNP_3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I, free and complexed cardiac troponin I, free cardiac troponin T, complexed cardiac troponin T, and free and complexed cardiac troponin T, and preferred assays are configured to detect these markers.

This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.

Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and/or collagen degradation, can be monitored within patient blood (serum) and/or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms.

The method for discriminating between benign and malignant prostate tumors relates to analyzing samples of blood, urine and tissue by fluorescence spectroscopy in order to detect the presence of naturally occurring molecules in the fluids and tissue that serve as biomarkers indicative of cancer in the human body. The analysis can be carried out based on fluorescence emission spectra, fluorescence excitation spectra and synchronous (emission and excitation) spectra of bio-samples. The detection, diagnosis, and follow-up and also discrimination between malignant and benign prostate tumors may be made by comparison of ratios of fluorescence emissions and/or excitation intensities of tryptophan, tyrosine, elastin, collagen, bile pigments, NADH, flavins and various species of porphyrins.

The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides. Methods of using these elastin digest comprising compositions for treating tissues in need of increased elasticity and or Elastin are described.

The invention relates to the use of angiogenic crystallin proteins to promote angiogenesis, wound healing and/or endothelial cell migration. Alpha A crystallin and βB2 crystallin have particular application in these methods. The crystallins will usually be in monomeric form. Typically, truncated form(s) of βB2 crystallin protein are utilized as can be prepared by partial hydrolysis of the protein by a protease enzyme such as elastase I. Methods for the purification of crystallin proteins from eye tissue are also described.

The invention relates to a skin compactness composition which comprises hyaluronic acid, hydrolyzed collagen, dipalmitoyl hydroxyproline, compound amino acid, decarboxylation peptide, acetyl hexapeptide, plankton extracts, lactic acid bacillus/soybean milk fermentation product filtrate, dipotassium glycyrrhizinate, retinyl palmitate, VE and hydrolyzed sesame protein. By the aid of anti-aging vitamin, amino acid, derivatives and peptides, an extracellular matrix structure matrix is endogenously improved, the dipalmitoyl hydroxyproline, palmityl glycine, the decarboxylation peptide, the acetyl hexapeptide, sodium hyaluronate, retinol, the hydrolyzed collagen, the plankton extracts, the lactic acid bacillus/soybean milk fermentation product filtrate and the dipotassium glycyrrhizinate serve as main components, thin wrinkles caused by skin laxity are comprehensively repaired, metalloprotease activity is inhibited by promoting collagen and elastin synthesis, skin compactness and elasticity are improved, and young skins are restored.

Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, collagen VI or a biologically active fragment or variant thereof and, optionally, one or more other ECM proteins (or fragments or variants thereof) such as elastin, fibronectin, vitronectin, tenascin, laminin, entactin, aggrecan, decorin, collagen I, collagen III, and collagen IV. Also, optionally present on the surface is one or more polycationic polymers, such as poly-D-lysine or poly-D-ornithine. This surface is used in cell culture to promote cell attachment, survival, and/or proliferation of a number of different cell types such as (a) liver cells (e.g., HepG2 tumor cells, and a newly discovered line of rat liver epithelial stem cells) (b) osteoblasts, such as the murine cell line MC3T3 cell line and (c) primary bone marrow cells. Kits comprising the surfaces and additional reagents are also disclosed.

The present invention is directed to a composition which is used to enhance the elasticity and/or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides or peptide-like compounds having low molecular weights and which substantially correspond to sequences found in elastin. The present composition specifically includes chemical modification of the peptides described herein, specifically carboxy and amino modification including the addition of amino acids to either end of the peptide fragments.

The invention discloses elastin-like polypeptides (ELP) for prokaryotic expression of fusion protein Prx by a non-digestion and non-chromatography purifying method and belongs to the field of genetic engineering. According to the elastin-like polypeptides, the type of the fourth amino acid in an elastin-like pentapeptide unit is changed and the elasticity function of the fourth amino acid is improved, and therefore, the reduction of the ELP length becomes possible. The ratio of K, V and F in the fourth basic group in the ELP pentapeptide unit is enabled to be 1: 6: 3. In terms of inteins, the high-efficiency intein gp41-1 is adopted; the C-terminal and the N-terminal of the intein are expressed separately, and the internal gene of the intein is mutated. The elastin-like polypeptides (ELPs) are ELP-IN and precursor protein ELP-IC-PrxI. The protein Prx is purified in a non-chromatography way by use of the elasticity function of the elastin-like polypeptides; no chromatographic column is required for separation, and the target protein precipitates by virtue of incubation at a certain temperature; besides, the precipitate can be re-dissolved in a buffer solution, and consequently, the protein can be purified more efficiently and quickly.

The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.

The present invention is directed to a composition which is used to enhance the elasticity and/or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides or peptide-like compounds having low molecular weights and which substantially correspond to sequences found in elastin. The present composition specifically includes chemical modification of the peptides described herein, specifically carboxy and amino modification including the addition of amino acids to either end of the peptide fragments.

The present invention is directed to a composition which is used to enhance the elasticity and/or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides having low molecular weights and which substantially correspond to sequences found in elastin. These peptides are used in conjunction with or in combination with retinoids, preferably tretinoin.

The invention discloses a double-targeting fusion protein based on elastin-like polypeptide (ELP), i.e., a double-targeting ELP/anti-EGFR nanometer antibody/iRGD fusion protein. The double-targeting fusion protein is prepared by constructing a recombinant plasmid containing ELP, an anti-EGFR nanometer antibody and an iRGD based on gene recombination technology and expressing and purifying the recombinant plasmid in Escherichia coli. The double-targeting fusion protein can be conjugated with the drug doxorubicin so as to form the ELP/anti-EGFR/iRGD double-targeting fusion protein doxorubicin conjugate. The ELP/anti-EGFR/iRGD double-targeting fusion protein doxorubicin conjugate has a hydration particle size of about 5 nm, mainly exists in the state of molecules and presents a good doxorubicin slow-release function and a good tumor cell-targeting function. The invention discloses a preparation method for the ELP/anti-EGFR/iRGD double-targeting fusion protein doxorubicin conjugate.

The invention provides a method for detecting post-transplantation GVHD related cytokines by using flow cytometry and a detection kit. The method and the detection kit have important clinical significance in the aspects of early evaluation and diagnosis of post-transplantation GVHD. According to the detection method and the kit, indexes of one or more different combinations of cell factors IL-6, IL-8, ST2, Reg3[alpha], Elafin, TNFR1, soluble IL-2R and HGF related to GVHD diagnosis and prognosis can be rapidly and homogeneously detected at the same time; single-sample multiple detection is achieved, time and resources are saved, and the result is automatically analyzed by software so as to be more objective and accurate. The method is simple, convenient, safe in detection and small in sample use quantity. By the application of the method, the risk of the GVHD of the transplanted patient can be evaluated timely, quickly and stably for a long time, the accuracy and timeliness of treatmentof the patient are improved, and the life of the patient is saved.

The invention relates to the technical field of food and medicines, and discloses a composition of a collagen peptide and an elastin peptide, and a preparation method and application of the composition. The composition of the present invention is composed of a collagen peptide and an elastin peptide, wherein the collagen peptide is produced by enzymolysis of a collagen material by pepsin or trypsin, and the elastin peptide is prepared by enzymolysis of an elastin material via papain and/or a complex protease Protamex. According to the present invention, the elastin peptide and collagen peptidein specific molecular weight ranges are prepared by specific processes, and form the composition at a suitable ratio. The composition can significantly increase the content of elastin and collagen indamaged skin at the same time in a small amount of use, significantly increase the content of hyaluronic acid and hydroxyproline and decrease the content of MMP3, and also can inhibit skin inflammatory factors.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

The invention relates to a high-expression recombination protein carrier pRELPN. The high-expression recombination protein carrier pRELPN is artificially synthesized ELP fusion protein(RELPN) consisting of 9 polyarginine (R9)-elastin polypeptide (ELP) n-10 poly asparagine (N10), when multiple clone sites cloned in pronucleus or eukaryotic expression vectors (p) are not directly expressed as exogenous genes, the effect of a second promoter can be achieved. The pRELPN carrier can promote independent high expression of an exogenous target gene behind start cipher ATG cloned behind ELP fusion protein. The fusion protein is seldom expressed, and self expression of hosts of escherichia coli or eukaryocyte and the like can be slightly restrained, so that recombination protein accumulation and high expression of the exogenous target gene can be promoted. The high expression vector pRELPN containing dual promoters is suitable for independent high expression of exogenous genes of antibodies, antigens, enzymes, recombination protein, polypeptide, ELP fusion protein and the like, so as to contribute to solving of the problem of disindustrialization caused by that a common expression vector islow or non in expression on an exogenous gene an exogenous gene or a fusion gene consisting of the exogenous gene and ELP.

The invention belongs to the field of biotechnology, and relates to amethod for preparing recombinant N-terminal brain natriuretic peptide precursor based on elastin-like label. The method comprises the following steps: cloning N-terminal brain natriuretic peptide gene onto a pET28a(+)/ELP[I]40 prokaryotic expression vector through genetic recombination, transferring the recombinant expression vector into Escherichia coli BL21(DE3) for expression, collecting thalli, then purifying the recombinant protein by adopting a repeated reversible transition cycling ITC method, wherein the protein is ELP[I]40-NT-proBNP recombinant protein. The method can fast, simply and efficiently purify a fusion protein with anti-NT-proBNP antibody binding activity, the recovery purity of the fusion expression protein can achieve 90% or more, thus providing a basis for preparing a standard substance with brain natriuretic peptide precursor antigenicity in high efficiency and low cost.

The invention relates to a method for purifying recombinant porcine circovirus 2 type Cap protein. The recombinant porcine circovirus 2 type Cap protein is composed of ELP type elastin polypeptide genes and PCV-ORF2 genes. A preparation method of the purifying recombinant porcine circovirus 2 type Cap protein comprises the steps of expression vector construction and fusion protein expressing and purifying. Compared with an existing porcine circovirus vaccine purifying method, the method for purifying the recombinant porcine circovirus 2 type Cap protein has the advantages that preparation is easy and convenient, purifying is easy, and the price is low, and is suitable for large-scale production operation, and a foundation is provided for preparation, purification and application of subsequent recombinant porcine circovirus subunit vaccines.